You are here

De-escalating therapy in IBD: when and how?

Filip Baert


Filip Baert is posed the question: should we de-escalate or stop treatment for patients with IBD in remission? He argues that we should not de-escalate or stop therapies in patients too early, except for selected patients for whom the risks have been identified as minimal.

Watch the full IBD12 presentation

De-escalating therapy in IBD: when and how?

Filip Baert

Related videos

Treatment of IBD in patients with past or current cancer

Laurent Beaugerie

Prof. Beaugerie states that immunosurveillance is essential in IBD patients with recently successfully treated cancer, and the use of immunosuppressants...

Relationship between diet and the microbiome

Philip Rosenstiel

Philip Rosenstiel asks: can we understand the microbiome and the inflammatory response? He explores the concept that diet and microbiota...

Drug levels: the future of personalised therapy?

Séverine Vermeire

Séverine Vermeire presents therapeutic drug and antibody monitoring as a helpful tool in optimizing and personalising the management of patients...



Subscribe to our E-Alert to stay informed of all new content as it's published on this platform.

IBD 13.03.2015

Visit the journal website!

Search form